Strata Critical Medical vs Tuniu
SRTA and TOUR side by side, both in transportation services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRTA and TOUR compare
Strata Critical Medical grew revenue faster over the last twelve months (66.8% versus 12.5% for Tuniu).
Strata Critical Medical keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with 5.4% at Tuniu.
Strata Critical Medical scores higher on the StockData Score (17 against 9 for Tuniu), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRTA | TOUR |
|---|---|---|
| Size and price | ||
| Market cap | $487M | – |
| Share price | $5.51 | $4.70 |
| Change, 1 year | 8.0% | −40.5% |
| Change, 5 years | −43.0% | −60.8% |
| Beta (5Y) | 1.63 | 0.36 |
| Employees | 601 | 856 |
| StockData Score | ||
| Total score | 17 (better) | 9 |
| Valuation score | 4 (better) | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 10.8× | – |
| P/S | 1.9× | – |
| P/B | 1.7× | – |
| FCF yield | −9.9% | – |
| Fair value | $8.72 | – |
| Margin of safety | 36.8% | – |
| Growth | ||
| Revenue growth (TTM) | 66.8% (better) | 12.5% |
| Revenue growth, 5Y average | 44.6% (better) | 5.1% |
| Net income growth (TTM) | – | −59.7% |
| EPS growth (TTM) | – | −57.1% |
| Profitability | ||
| Gross margin | 20.6% | 58.0% (better) |
| Operating margin | −8.0% | 1.9% (better) |
| Net margin | 15.7% (better) | 5.4% |
| FCF margin | −18.9% (better) | −20.1% |
| Return on equity | 16.0% (better) | 2.9% |
| Return on invested capital | −8.8% | 11.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Net debt / EBITDA | – | −94.43 |
| Interest coverage | – | 5.6× |
| Current ratio | 2.64 (better) | 2.04 |
| Altman Z-score | 5.67 | – |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Payout ratio | – | 95.7% |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 63.0% | 0.17% |
| Held by insiders | 21.0% | 65.2% |
| Insider net buying, 12 months | −$724K | $38.2K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.5% | – |
Go deeper
- SRTA stock overview
- SRTA income statement
- SRTA valuation and score
- TOUR stock overview
- TOUR income statement
- TOUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.